融合蛋白开发加速推进：HanchorBio 与药明生物合作背后

世易药研01-30

随着新一代生物药物形态不断向复杂化、多功能化演进，研发与制造端所面临的技术挑战也在同步上升。近日，处于临床阶段的Biotech公司汉康生技（HanchorBio）与CRDMO企业药明生物宣布达成战略合作，双方将围绕多款双功能及多功能融合蛋白项目展开协作，共同推进相关项目从早期临床转化至后期生产阶段。该合作于2026年1月26日正式对外公布。根据协议内容，药明生物将为汉康生技提供一体化生物药服务，...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2607167012?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-01-30 11:25","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2607167012","market":"hk","top_or_hot":-1,"title":"融合蛋白开发加速推进：HanchorBio 与药明生物合作背后","media":"世易药研","content":"<div>\n<p>随着新一代生物药物形态不断向复杂化、多功能化演进，研发与制造端所面临的技术挑战也在同步上升。近日，处于临床阶段的Biotech公司汉康生技（HanchorBio）与CRDMO企业药明生物宣布达成战略合作，双方将围绕多款双功能及多功能融合蛋白项目展开协作，共同推进相关项目从早期临床转化至后期生产阶段。该合作于2026年1月26日正式对外公布。根据协议内容，药明生物将为汉康生技提供一体化生物药服务，...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260130120117953f0c30&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>融合蛋白开发加速推进：HanchorBio 与药明生物合作背后</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n融合蛋白开发加速推进：HanchorBio 与药明生物合作背后\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-30 11:25 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260130120117953f0c30&s=b><strong>世易药研</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>随着新一代生物药物形态不断向复杂化、多功能化演进，研发与制造端所面临的技术挑战也在同步上升。近日，处于临床阶段的Biotech公司汉康生技（HanchorBio）与CRDMO企业药明生物宣布达成战略合作，双方将围绕多款双功能及多功能融合蛋白项目展开协作，共同推进相关项目从早期临床转化至后期生产阶段。该合作于2026年1月26日正式对外公布。根据协议内容，药明生物将为汉康生技提供一体化生物药服务，...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260130120117953f0c30&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1589","symbol_name":"北水核心资产","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260130120117953f0c30&s=b","article_id":"2607167012","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260130120117953f0c30&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2607167012","pubTimestamp":1769743538,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"近日，处于临床阶段的Biotech公司汉康生技与CRDMO企业药明生物宣布达成战略合作，双方将围绕多款双功能及多功能融合蛋白项目展开协作，共同推进相关项目从早期临床转化至后期生产阶段。通过整合技术平台与制造能力，双方希望加快融合蛋白项目的开发进程，推动创新疗法惠及全球患者。合作背后的开发模式考量对于汉康生技而言，此次与药明生物的合作，有助于在保持研发推进速度的同时，提升制造环节的灵活性与可扩展性。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1589":"北水核心资产","LU0039217434.USD":"HSBC GIF CHINESE EQUITY \"AD\" INC","LU0516423174.USD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (USD) ACC","LU0516422952.EUR":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (EUR) ACC","LU0140636845.USD":"施罗德大中华区股票A Acc","LU0307460666.USD":"EASTSPRING INVESTMENTS CHINA EQUITY \"A\" ACC","BK1141":"生命科学工具和服务","LU0823426308.USD":"法巴中国股票基金","LU0417516738.SGD":"Allianz Hong Kong Equity AT Acc SGD","LU0043850808.USD":"HSBC GIF ASIA EX JAPAN EQUITY \"AD\" INC","BK1576":"医药外包概念","LU1242518931.SGD":"Fullerton Lux Funds - Asia Absolute Alpha A Acc SGD","LU0588546209.SGD":"Eastspring Investments - China Equity Fund AS SGD","LU0823426480.USD":"法巴中国股票经典Dis","LU0348735423.USD":"ALLIANZ HONG KONG EQUITY \"A\" (USD) INC","BK1610":"ETF&股票定投概念","LU0856984785.SGD":"HSBC GIF MANAGED SOLUTIONS ASIA FOCUSED GROWTH \"ACH\" (SGDHDG) ACC","LU1880383366.USD":"东方汇理中国股票基金 A2 (C)","LU0359201612.USD":"贝莱德中国基金A2","02269":"药明生物","SG9999002562.SGD":"LionGlobal Asia Pacific SGD","LU1242518857.USD":"FULLERTON LUX FUNDS - ASIA ABSOLUTE ALPHA \"I\" (USD) ACC","LU0456846285.SGD":"JPMorgan Funds - Greater China A (acc) SGD","LU0359202008.SGD":"Blackrock China Fund A2 SGD-H","LU0979878070.USD":"FULLERTON LUX FUNDS - ASIA ABSOLUTE ALPHA \"A\" (USD) ACC","LU0051755006.USD":"摩根大通中国A (dist)","LU1688375341.USD":"贝莱德中国灵活股票基金","LU0819121731.USD":"HSBC GIF MANAGED SOLUTIONS ASIA FOCUSED GROWTH \"AC\" (USD) ACC","LU0516422366.SGD":"Fullerton Lux Funds - Asia Focus Equities A Acc SGD","SG9999002463.SGD":"LionGlobal China Growth SGD","LU1720050803.USD":"安联全方位中国股票基金","LU0181495838.USD":"施罗德新兴亚洲A Acc","LU0572944931.SGD":"Janus Henderson Horizon China Opportunities A2 SGD","LU0456827905.SGD":"JPMorgan Funds - China A (acc) SGD","LU0326950275.SGD":"Schroder ISF China Opportunities A Acc SGD-H","LU0516423091.SGD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (SGD) ACC","LU0417516902.SGD":"Allianz China Equity Cl AT Acc SGD","LU0348825331.USD":"ALLIANZ CHINA EQUITY \"A\" (USD) INC","IE00B0JY6N72.USD":"PINEBRIDGE GLOBAL EMERGING MARKETS FOCUS EQUITY \"A\" (USD) ACC","LU0052750758.USD":"富兰克林中国基金A Acc","LU0320764599.SGD":"FTIF - Templeton China A Acc SGD","BK1521":"挪威政府全球养老基金持仓","LU1794554557.SGD":"Allianz All China Equity AT Acc H2-SGD","LU0708995583.HKD":"TEMPLETON CHINA \"A\" (HKD) ACC","LU2039709279.SGD":"MANULIFE GF DRAGON GROWTH \"AA\" (SGDHDG) INC","LU3063872942.SGD":"FULLERTON LUX FUNDS ASIA EQUITIES \"I\" (SGD) ACC","LU0516422440.USD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"A\" (USD) ACC","LU0327786744.USD":"Janus Henderson Horizon China Opportunities A2 USD"},"translate_title":"Fusion protein development accelerates: behind the cooperation between HanchorBio and WuXi Biologics","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02269":1.5},"content_text":"随着新一代生物药物形态不断向复杂化、多功能化演进，研发与制造端所面临的技术挑战也在同步上升。近日，处于临床阶段的Biotech公司汉康生技（HanchorBio）与CRDMO企业药明生物宣布达成战略合作，双方将围绕多款双功能及多功能融合蛋白项目展开协作，共同推进相关项目从早期临床转化至后期生产阶段。该合作于2026年1月26日正式对外公布。根据协议内容，药明生物将为汉康生技提供一体化生物药服务，覆盖细胞株构建、工艺与生物分析方法开发、制剂研究以及符合监管要求的生产制造等关键环节。这一合作模式旨在应对融合蛋白等新型生物大分子在开发和放大过程中所面临的复杂性挑战。汉康生技的融合蛋白项目源自其核心技术FBDB™ (Fc-Based Designer Biologics平台，主要利用抗体Fc区域为骨架，并透过蛋白质工程技术，将改造后的多种抗癌大分子建构在其骨架上，以及结合AI辅助设计的药物开发能力，致力于解决肿瘤免疫治疗中的难题。药明生物首席执行官陈智胜博士在新闻稿中表示，此次合作体现了汉康生技对药明生物端到端综合能力的认可，尤其是在复杂生物药物开发方面的经验与质量体系。通过整合技术平台与制造能力，双方希望加快融合蛋白项目的开发进程，推动创新疗法惠及全球患者。融合蛋白为何在研发管线中持续升温随着融合蛋白及其他多特异性分子逐步进入临床中后期阶段，开发企业和制造方正面临更高要求，包括分子结构复杂度、工艺稳健性以及规模化生产能力等多个方面。为降低技术风险、避免在临床推进过程中出现延误，研发、工艺与制造环节的早期协同，正成为行业内的共识。在肿瘤和免疫介导疾病领域，融合蛋白被认为是一种实现差异化作用机制的重要方式，尤其是在第一代免疫治疗手段逐渐显现局限性的背景下。与双特异性抗体、抗体偶联药物（ADC）等形式一道，融合蛋白已在当前生物药研发管线中占据相当比重。药明生物方面披露，其综合服务平台所支持的项目中，大多数涉及结构和工艺更为复杂的生物药物形式。这一趋势也进一步凸显了开发方对具备复杂分子管理经验、完善质量体系以及全球监管应对能力的合作伙伴的依赖。合作背后的开发模式考量对于汉康生技而言，此次与药明生物的合作，有助于在保持研发推进速度的同时，提升制造环节的灵活性与可扩展性。相较于自建生产和开发体系，公司选择将平台型创新与外部成熟的开发制造能力相结合，以支持多条融合蛋白管线在不同临床阶段、不同地区同步推进。这一做法也反映了当前不少新兴生物技术公司的普遍选择，即通过外部合作实现资本效率更高的研发模式，在控制风险的同时加快项目进展。汉康生技创始人、董事长兼首席执行官刘世高表示，与药明生物的合作将有助于公司将平台驱动的创新转化为高质量的临床和商业化资产。在推进多款新一代融合蛋白项目的过程中，执行效率、制造可靠性以及规模化能力是关键考量因素。对未来生物药开发模式的启示从更广泛的行业层面来看，此次合作体现了药物研发企业与合同研发生产机构在应对先进生物药技术要求提升过程中的角色变化。随着融合蛋白及其他多功能分子逐步走向全球临床开发，一体化开发与制造模式在项目效率、规模化能力以及长期可行性方面的重要性，正在不断提升。在这一背景下，类似汉康生技与药明生物之间的合作，或将成为支持复杂生物药物持续推进的重要实践路径之一。内容来源：","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2607167012","isCrawlerRequest":true}